ERBB2 and cancer: Highly expressed GSDMB is also linked to tumor aggressiveness in several types of cancers, such as gastric, hepatic, colon, and cervical cancer,124, 148, 151 as well human epidermal growth factor receptor 2 (HER2)‐positive breast cancer with poor prognosis,106, 118, 152, 153 and pancreatic cancer susceptibility (false discovery rate ≤ 0.05),117 implying the role of GSDMB as an oncogene and potential attractive therapeutic target in metastasis, poor prognosis, and drug resistance to anti‐HER2 therapy.